[Charts] Three Bullish Tailwinds for Biotech

You're receiving this email as part of your subscription to Trend Trader Daily. [Unsubscribe here](. [Charts] Three Bullish Tailwinds for Biotech By Lou Basenese Friday, April 23, 2021 Yesterday, I responded in a cheeky fashion to the haters about the recent underperformance of small- and micro-cap stocks. (It’s a must-read. So if you missed out, you can catch up [here](.) Today, we’re turning our attention to another investment I’ve been super-bullish on for the last year: biotech. Just like small- and micro-cap stocks, biotech’s been suffering through a slowdown. But as you’ll see in a moment, there’s no reason to panic (or sell) here, either… ADVERTISEMENT Want the chance to capture BIG sudden moves like this... As soon as the market opens? [>> RSVP for Lou's "24-Hour Gains" Event Right Here]( >> Look Out Below! In case you didn’t notice, the major biotech indexes have been selling off sharply since early February. (click image to enlarge) Furthermore, the smaller the company, the more severe the sell-off has been. Consider: - The large- and mega-cap biased iShares Nasdaq Biotechnology ETF (IBB) has been down as much as 13%. - The SPDR S&P Biotech ETF (XBI), which has more exposure to small- and mid-cap biotechs, has been down as much as 24% — nearly double the drawdown for IBB. - And the smallest biotechs are down roughly double that amount, about 50%. But don’t fret. Here are three major bullish factors to keep in mind… Fundamentals, Financings, and Seasons First, for the majority of biotechs I’ve been recommending, nothing has fundamentally changed for the worse. If anything, the fundamentals keep getting better. And eventually, the stock prices will reflect this reality. Or as famed value investor Benjamin Graham noted, “In the short run, the market is a voting machine but in the long run, it is a weighing machine.” (click image to enlarge) Second, venture capital funding for biotechs, a key leading indicator, remains at record levels. In fact, U.S.-based biotechs raised a record $12 billion in venture funding in the first quarter, according to Pitchbook. Even more impressive, that marks the fourth quarter in a row of chart-topping funding. We couldn’t ask for a more robust and bullish funding environment for innovation in biotech. Third, we’re about to enter a historically strong performance season for biotechs. As you can see in the chart below, biotechs have surged pretty much every April/May through July for five years (and counting): (click image to enlarge) In other words, the old market adage to “Sell in May and Go Away” should never be applied to biotechs. Remember, the chart above is for the major biotech index, which represents the average seasonal rally in biotechs for mostly large- and mega-cap companies. That means, when the seasonal biotech surge hits again, we can expect our small- and micro-cap biotechs to rally way more. That’s not merely hopeful talk, mind you. I’m betting on it with my own money, too. And in upcoming updates, I’ll share what companies I’m betting the most on. Performing Over Time So stay tuned… Stay calm… And remember what market-beating value manager Robert Olstein says (emphasis mine), “The desire to perform all the time is usually a barrier to performing over time.” The investments we focus on here are designed to perform over time, not all the time. In fact, many have already performed — and based on my research, I have full confidence that the others will eventually perform, too. So, any other (cheeky) questions for me this week? (click image to enlarge) Ahead of the tape, [Lou Basenese] Lou Basenese [Terms & Privacy](| [Unsubscribe]( 301 S. Perimeter Park Dr. Suite 100 Nashville, Tennessee 37211 RISK NOTICE: All investing comes with risk. That includes the investments teased in this letter. You should never invest more than you can afford to lose. Please use this research for the purpose that it's intended — as research only. You should consult a professional financial advisor before ever taking a position in any securities you see herein. SECURITY HOLDING NOTICE: Although we are never compensated from any companies for coverage, you should be aware that Trend Trader Daily, its authors, its owners, and its employees may purchase, sell, or hold long or short positions in securities of the companies mentioned in this communication. While authors might actively transact in the securities mentioned, they will always have a net position that is consistent with the position set forth in our research reports, letters and updates. DISCLAIMERS: The work included in this communication is based on diverse sources including SEC filings, current events, interviews, corporate press releases, and information published on funding platforms, but the views we express and the conclusions we reach are our own. As such, this content may contain errors, and any investments described in this content should be made only after reviewing the filings and/or financial statements of the company, and only after consulting with your investment advisor. Actual results may differ significantly from the results described herein. Furthermore, nothing published by Trend Trader Daily, Inc should be considered personalized financial advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular investment situation. No communication by our employees to you should be deemed as personalized investment advice. Trend Trader Daily is an independent provider of education, information and research on publicly traded companies, and as such, it accepts no direct or indirect compensation from any companies or third parties mentioned in any of our letters, reports or updates. - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -